CD36 and cancer: Of interest is the observed downregulation of CAV1 and CD36, both of which are involved in lipid metabolism and metabolic reprogramming of MDSC, and mycobacterial infections, and are associated with poor clinical outcomes in malignant tumors (59, 60).